- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
June 29th, 2010
Venture capitalists and their limited partners have long bemoaned lackluster returns and the lengthening time until exits for portfolio companies. Publicly held venture firm Harris & Harris Group has gotten tired of waiting, and said it plans to invest more in public companies in a bid to make faster returns.
Since 2002, Harris & Harris has focused on backing companies with products based on nanotechnology or microsystems. Its private-company portfolio includes Mersana Therapeutics Inc., which develops cancer therapies based on its biodegradable polymer technology, and Solazyme Inc., which uses algae to produce clean fuels, chemicals, foods and health-science products.
|Related News Press|
News and information
Graphene under pressure August 26th, 2016
Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016
Leading Advanced Materials Manufacturer Pixelligent Closes $10.4 Million in Funding: Capital Will Boost Capacity for North American Manufacturing, Drive Asian Expansion, and Continue Innovation in Solid State Lighting and OLED Display Applications August 16th, 2016
Harris & Harris Group to Host a Shareholder Update Call, Including a Presentation by One of Its Precision Health and Medicine Portfolio Companies, Muses Labs, Inc., on August 23, 2016 August 16th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016
Nanobiotix revenue for Q2 2016 July 14th, 2016